Endpoint · inferenceGETx402-filings.datalayer.workers.dev /v1/health/clinical-trials ?condition=melanoma&intervention=pembrolizumab&limit=25&phase=PHASE3&sponsor=Novartis&stoppedOnly=true
Stopped clinical trials with the stop reason classified.
Read more
Stopped clinical trials with the stop reason classified. ClinicalTrials.gov records why a trial halted as free text; this reads that text and separates safety and efficacy failures from business, recruitment and funding stops, which are the ones people routinely misread as drug failures. Filter by sponsor, condition, intervention and phase, and get the cohort-level breakdown alongside the records.Overview
Grade?
UNRATED
0 of 30 paid calls toward a letter
Price
$0.02 per call
Paid calls
none yet
delivery unknown until someone pays
More info
Seller?
URL
https://x402-filings.datalayer.workers.dev/v1/health/clinical-trials?condition=melanoma&intervention=pembrolizumab&limit=25&phase=PHASE3&sponsor=Novartis&stoppedOnly=true
Seen
first 35 days ago · last 18 days ago
45 free handshakes
Payment
Pays through
x402
Offered on?
Base USDC
Listed on?
Base
Score, from free handshakes onlyweights 2026.09.3
UN
RATED
RATED
0.781 liveness verified, no letter
To a letter · 30 paid calls
0 of 30
Held back by sample size, not by the seller · gap to 1.000 is 0.219: 0.143 uncertain ? + 0.076 short ? · 0.019 to B
| Component | Weight | Measured | Lower bound ? | Adds | Short ? | Uncertain ? | |
|---|---|---|---|---|---|---|---|
| latency p95costs the most it answered as fast as its class |
0.20 | 0.62 | 0.335 | 0.067 | −0.076 | −0.057 | |
| liveness it answered at all |
0.60 | 1.00 | 0.857 | 0.514 | 0 | −0.086 | |
| price stability the price stayed where it was listed |
0.20 | 1.00 | 1.000 | 0.200 | 0 | 0 | |
| Composite | 1.00 | 0.781 | gap to 1.000 = 0.219 · 0.076 short · 0.143 uncertain | 0.781 | −0.076 | −0.143 |
Not measured: correctness · nobody paid; honesty · nobody paid; schema conformance · no answer had a published shape to check
The multiplication, written out
0.200 × 0.335 latency p95
+ 0.600 × 0.857 liveness
+ 0.200 × 1.000 price stability
= 0.781 → UNRATED: 43 of 30 paid calls weights 2026.09.3 · 43 samples · seed cap_01M1A59XTWH66SE05QXRPQ97S8|2026-08-23T01:00:44.739Z|2026.09.3
Verify it yourself
npx teppi-check https://x402-filings.datalayer.workers.dev/v1/health/clinical-trials?condition=melanoma&intervention=pembrolizumab&limit=25&phase=PHASE3&sponsor=Novartis&stoppedOnly=truecurl -s https://api.teppi.xyz/v1/trust/cap_01M1A59XTWH66SE05QXRPQ97S8